An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis

1. Must have completed a selected Novartis MS study which dosed ofatumumab 20 mg sc every
4 weeks

2. Written informed consent

Exclusion Criteria:

– Emergence of any clinically significant condition/disease during the previous
ofatumumab study in which study participation might result in safety risk for the
subject

– Subjects with active systemic bacterial, viral or fingal infections, or chronic
infection (e.g. AIDS)

– Subjects taking medications prohibited by the protocol

– Pregnant or nursing (lactating) women Other protocol-defined inclusion/exclusion
criteria may apply

Vaccination sub-study:

Inclusion criteria

1. Informed consent

2. Actively enrolled in the COMB157G2399 Study

3. 12 weeks of continuous treatment within the COMB157G2399 Study

4. prior vaccination history as per protocol-defined

Exclusion criteria

– known hypersensitivity or history of systemic allergic, neurologic or other reactions
to vaccines

– allergies to egg or shellfish

– any safety findings including low IgG/IgM requiring ofatumumab interruption within 12
weeks prior to vaccination sub-study start

– any major episode of infection requiring hospitalization or treatment with intravenous
antibiotics within 2 weeks of the first vaccination sub-study visit

Other protocol-defined inclusion/exclusion criteria may apply